New White Paper by Cowen Royalty and Health Advances Provides Key Solutions
for Long-Term Financial Success
STAMFORD, Conn. and WESTON, Mass., Nov. 6 /PRNewswire/ -- Those
biopharmaceutical companies that are able to incorporate innovative and
flexible elements into their business models will be best positioned to
survive healthcare reform and maintain attractive long-term returns, according
to a white paper published today by Cowen Healthcare Royalty Partners, a
global healthcare private equity firm, and Health Advances, a leading
healthcare strategy firm.
The paper, "Maintaining Attractive Biopharma Returns in the Face of Healthcare
Reform", examines key issues at the center of the debate including access to
care, controlling costs, drug pricing and value-based healthcare. In addition
to discussing the increased pressures biopharma companies face, including the
restrictive use of branded drugs for large patient populations and follow-on
biologics, the paper outlines new solutions companies can implement to achieve
the same levels of return for its investments as it has in the past.
Some of the paper's key findings include:
-- Biopharma companies need to adapt their business models to maintain
attractive ROIs such as exploring pay-for-performance relationships
with
stakeholders, cost-effective care solutions that align incentives, and
investing in follow-on biologics and/or generics
-- Investing in pharmacoeconomic competencies and integrating these into
clinical development will mitigate reimbursement risk
-- Investing in personalized healthcare and specifically biomarkers will
be
rewarded
-- Highly differentiated products addressing niche markets will be the
least vulnerable even if stringent regulation is passed
Gregory B. Brown, M.D., Co-Founder and Managing Director of Cowen Royalty,
commented, "Healthcare reform is a serious issue for biopharma companies who
are already feeling pressure from patent expirations, fewer drug approvals and
growing development costs. We partnered with Health Advances to bring a new
and unique perspective on the healthcare debate especially as it relates to
biopharma companies -- the developers of many of our future medicines."
To download a copy of the white paper visit
http://www.cowenroyalty.com/content/news/publications-presentations.htm.
About Cowen Healthcare Royalty Partners:
Cowen Healthcare Royalty Partners is a global healthcare private equity firm
that invests principally in commercial-stage biopharmaceutical and medical
device companies and products, through the purchase of royalty interests. The
investment team has over 100 years of healthcare related experience including
principal investing, structured finance, healthcare industry senior
management, Wall Street research and consulting, scientific and clinical
experience. For more information, visit www.cowenroyalty.com.
About Health Advances:
Founded in 1992, Health Advances is a leading healthcare strategy firm
advising clients in the biopharma, device and diagnostic sectors. Industry
executives and investors rely on Health Advances to advise them on their most
challenging commercial decisions. For more information regarding our
consulting services, visit www.healthadvances.com.
Media Contact:
Kellie Walsh
914-315-6072
kwalsh@kwmcommunications.com
SOURCE Cowen Healthcare Royalty Partners
Kellie Walsh, +1-914-315-6072, kwalsh@kwmcommunications.com
